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The Jehovah’s Witness religious movement  is a Christian sect
with over 2.6 million followers worldwide that forbids the
transfusion of blood and blood components to its members.1
There is limited experience in the treatment of Jehovah’s
Witnesses with acute myeloid leukemia (AML). Treatment of
patients, who  do not accept required blood support on reli-
gious grounds, is always a difﬁcult problem. This dilemma is
of particular concern in cases such as acute leukemia in which
the physician himself, by choosing and applying appropriate
treatment, may increase the need for transfusion support.2
The standard treatment for AML  is seven days of an
anthracycline and three days of cytarabine (7 + 3); with this
regimen 70–80% of young adults and 40–60% of older adults,
will achieve complete remission.3 The combination of cytara-
bine plus an anthracycline results in severe pancytopenia
and therefore requires transfusion support.4 During induction
chemotherapy, patients are given an average of 10.8 units of
red blood cell concentrates and 8.5 platelet transfusions over
a period of about 30 days.5
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open  access article under the CC BY-NC-ND license (http://creativecomCorsetti et al. described a chemotherapy regimen designed
for elderly AML patients that had low hematological toxicity,
and response rates of 36%.6 In this setting, another drug, aza-
cytidine is used to treat AML  in elderly or fragile patients who
are not candidates for an intensive chemotherapy regimen.7
However, since azacytidine was not available at our institution
due to ﬁnancial restrictions, we  administered a combination
of low-dose cytarabine plus valproic acid to our patient after
she rejected standard AML therapy.
Case  report
In June 2014, a 35-year-old female Jehovah’s Witness presented
weakness, fatigue, malaise and skin lesions of one month’s
duration. Peripheral blood was tested and her complete blood
count (CBC) gave a hemoglobin (Hb) level of 8.6 g/dL, an ele-
vated white blood cell count (WBC) of 30 × 109/L and a platelet
9a de Nuevo León, Av. Madero y Gonzalitos, Col. Mitras Centro,
aujo).
Upon physical examination of the skin, painless, nodular
and violaceous lesions disseminated on the face, neck, trunk
and extremities were identiﬁed as myeloid sarcomas. She also
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
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resented with swollen and spongy gums and a soft painful
nd tender tissue tumor on the right side of the neck with a
ean diameter of 6 cm.
A bone marrow aspiration revealed a hypercellular mar-
ow with 70% monoblasts. Flow cytometry was performed
evealing an aberrant immunophenotype consisting of two
opulations of blasts: the ﬁrst was HLA-DR+, CD13+, CD33+
eak, CD34+, CD45+ weak, CD64+, CD117+, MPO+ in 50%, and
he second population included 13% of the blasts with a
LA-DR+, CD33+, CD34+ weak, CD45+, CD56+, CD64+, CD123+,
POc+ phenotype. Cytogenetic and molecular studies were
ot performed. She was diagnosed with AML not otherwise
peciﬁed using the World Health Organization Classiﬁca-
ion. Biopsies of the skin and the soft tissue tumor were
erformed showing an inﬁltrate of monocytoid cells (MPO+,
D68+, CD34+, CD117+), which was consistent with leukemia
utis.
The patient and family were informed that the appropriate
reatment (7 + 3) implied marked and prolonged myelosup-
ression requiring transfusion support, and the patient
efused to grant consent for transfusions. A minimally myelo-
uppressive treatment plan consisting only of vinblastine for
ytoreduction was then proposed and accepted. The patient
as fully aware of the reduced probability of achieving a
urable complete remission.
She was hospitalized at diagnosis and 10 mg  of vin-
lastine was administered for cytoreduction. The next day
he WBC  count was 17.4 × 109/L. Four days later, the WBC
as 4.5 × 109/L, Hb was 7.7 g/dL and the platelet count was
9 × 109/L.
A week later, she complained about progressive dyspha-
ia and an increase in the myeloid sarcomas to about 10 cm.
er CBC revealed WBC  15 × 109/L, Hb 8 g/dL and platelet count
00 × 109/L. She received 17 mg mitoxantrone and intermedi-
te dose of Ara-C (two doses of 1.5 g IV b.i.d.). The next day
oth the dysphagia and tumor mass disappeared. Treatment
as uneventful, with neither infectious nor hemorrhagic com-
lications, however on Day +12 she presented with severe
ancytopenia [Hb: 6 g/dL, absolute neutrophil count (ANC): 0,
latelet count: 30 × 109/L], therefore we  decided to change the
reatment regimen and low dose Ara-C and valproic acid were
iven in an outpatient setting.
A month later (Day +26) her CBC revealed Hb 9.1 g/dL,
BC  4.05 × 109/L, ANC 0, and platelet count 130 × 109/L. She
eceived Ara-C (20 mg  b.i.d.) as a subcutaneous injection for
our days, subsequent courses of low dose Ara-C were planned
fter at least 21 days, with valproic acid starting at 5 mg/kg
aily divided in two equal doses. Dose escalation of val-
roic acid was carried out according to patient tolerance until
he plasma therapeutic range (50–100 mcg/mL)  was reached.
his patient also received prophylactic antibiotics if the ANC
ropped below 0.5 × 109/L. She received levoﬂoxacin (500 mg
O every day), acyclovir (400 mg b.i.d.) and itraconazole (100 mg
aily). The patient refused erythropoietin due to religious
eliefs. In every cycle one more  day of Ara-C was added if
he Hb was >7 g/dL and platelet count >30 × 109/L. During the
ixth course she received seven days of Ara-C, after which
evere cytopenias developed; it was decided to reduce the
ra-C to six days in the next course. In the eighth cycle, she
resented with hyperleukocytosis (176 × 109/L) and the size of 1 6;3  8(4):358–360 359
the myeloid sarcomas increased. At that time, 10 mg  of vin-
blastine were again administered, and cytoreduction (WBC
3.05 × 109/L) with ANC 0 was obtained, along with reduction
in the size of the sarcomas.
She received eight courses of treatment without transfu-
sions or infectious complications visiting the outpatient clinic
for a checkup twice a week; during this time, she was able to
perform her basic daily activities, social and religious.
After the last course of therapy, she presented a cough with
expectoration but was afebrile. A chest X-ray revealed bilat-
eral peripheral pulmonary inﬁltrates consistent with bilateral
pneumonia of unknown etiology. She refused to be hospital-
ized and was managed with antibiotics at home. The patient
died eight months after diagnosis.
Discussion
There is only one report of successful remission induction
using standard chemotherapy (7 + 3) in a Jehovah’s Witness
with AML.8 In another report, a 20-year-old woman was
diagnosed with AML  by morphology in 1979, but without
molecular, cytogenetics or ﬂow cytometry conﬁrmatory stud-
ies. She was treated with vincristine, prednisone and Ara-C
and was cured at the time of the report.9 On the grounds
of having only a morphology diagnosis and the patient
responded to that speciﬁc treatment, we hypothesize that this
case may have been a lymphoblastic leukemia. There are other
case reports on patients surviving longer than our patient,
however all were treated in an inpatient setting, and/or had
infectious complications.10
We  acknowledge that azacitidine is a therapeutic option for
patients with myelodysplastic syndromes and older patients
with AML.11 Its use in a Jehovah’s Witness has been reported,
however because of its elevated costs it was not a valid option
for this patient.
Herein we report our experience treating a Jehovah’s Wit-
ness using vinblastine, low dose Ara-C and valproic acid
but without blood transfusions, based on a treatment for
elderly patients published by Corsetti et al.6 who  reported
an overall response rate of 35% and an overall median sur-
vival of eight months (range: 2–36). These authors included
histone deacetylase inhibitors, such as valproic acid, which
have a proven efﬁcient to overcome differentiation arrest of
AML  blasts.12 We  decided to use this regimen because of
its response rates. Low dose Ara-C has been used in several
regimens of phase II trials for AML for several years giving
responses that include complete response.13 This therapy is
well tolerated and can be given in an outpatient or home care
setting.
Vinblastine is a drug rarely used in the treatment of
AML. Vinca alkaloids, such as vinblastine, target microtubule
dynamics by binding to tubulin monomers and dimers.14 They
have been used in relapse or refractory AML  patients. There
are some studies using vinblastine in combination therapy
with Ara-C, VP 16-213 (etoposide) and vincristine for relapsed
AML.15 The drug has been used as monotherapy in children
with AML, with a reported remission rate of 53%.16
Gómez-Almaguer et al. reported reduction of blasts in
peripheral blood of AML patients after the administration of
oter.
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vinblastine, with a 77% response rate of patients within the
ﬁrst weeks of treatment. Thus, vinblastine is a less costly and
less toxic option for palliative cytoreduction.17 Our patient ini-
tially received vinblastine alone, but a week later, the mass
reappeared. So we  concluded that vinblastine can be used at
the start of the treatment to decrease tumor burden in LMA,
but it should be followed by supplementary therapy. We  did
not know whether vinblastine would lead to additional trans-
fusion requirements, but in the experience of our service, it
is a safe drug to reduce or eliminate the necessity of blood
transfusions in elderly people or in palliative care treatment.
Conclusion
We  administered a combination of Ara-C and valproic acid in
our AML  patient, together with vinblastine when there was
a high tumor burden. This regimen was well tolerated, with
good response and regression of extramedullary inﬁltration.
The patient survived for eight months without transfusions
or infectious complications, and she was hospitalized only
at diagnosis receiving the rest of the therapy as an outpa-
tient. The alternative treatment described appears to be a valid
option that offers an acceptable quality of life for AML patients
refusing standard treatment that includes transfusions and
hospitalization.
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